XERIS PHARMACEUTICALS INC

XERIS PHARMACEUTICALS INC insiders are currently net buyers of XERS stock, showing bullish sentiment over the past 90 days. Executives have purchased $31.4M while selling $7.1M, resulting in a positive net flow of $24.4M. This buying activity represents 82% of total transaction volume.

XERIS PHARMACEUTICALS INC has 26 active insiders who have filed SEC Form 4 transactions in the past 90 days. Mgmt Iii, L.p. Deerfield (Executive) leads with 4 transactions totaling $11.3M. Group, Llc Redmile (Executive) follows with 2 transactions worth $10.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. XERIS PHARMACEUTICALS INC's current score of 82/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $31.4M in purchases versus $7.1M in sales.

The most recent insider transaction occurred on Jul 1, 2026, when Kreher Nerissa (Executive) acquired 37,910 shares at $8.00 per share for $303.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, XERS insider trading sentiment is currently bullish with an Alignment Score of 82/100. The net insider flow of $24.4M reflects accumulation, with 82% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like XERIS PHARMACEUTICALS INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At XERS, we track all Form 4 filings—currently showing 264 transactions from 26 insiders over 90 days.

A 10b5-1 plan allows XERIS PHARMACEUTICALS INC executives to pre-schedule stock sales when they don't possess material non-public information. At XERS, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at XERS appears discretionary, making insider signals more meaningful.

You can monitor XERIS PHARMACEUTICALS INC (XERS) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 26 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. XERIS PHARMACEUTICALS INC's current score of 82/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $31.4M in purchases versus $7.1M in sales over 90 days, resulting in a net flow of $24.4M.

SEC Form 4 filings are mandatory reports that XERIS PHARMACEUTICALS INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At XERS, the most common type is "A" with 20 occurrences. The most recent Form 4 was filed on Jul 1, 2026 by Kreher Nerissa.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At XERIS PHARMACEUTICALS INC, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at XERS represents discretionary decisions with more informational value.